Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity

Autor: Paul M. Daniel, Frédéric Hollande, Andrew P. Morokoff, Gulay Filiz, Sebastian Dworkin, Theo Mantamadiotis, Daniel Brown, Wayne Ng, Nicole Kountouri, Stephanie Amiridis
Rok vydání: 2023
Předmět:
0301 basic medicine
Pathology
medicine.medical_treatment
Immunofluorescence
Cancer Treatment
lcsh:Medicine
Drug resistance
Mice
Basic Helix-Loop-Helix Transcription Factors
Medicine and Health Sciences
Morphogenesis
AC133 Antigen
Cell Cycle and Cell Division
lcsh:Science
Hypoxia
Research Integrity
Uncategorized
Mice
Inbred BALB C
Multidisciplinary
biology
Brain Neoplasms
Stem Cell Therapy
Stem-cell therapy
Phenotype
Hyaluronan Receptors
Oncology
Cell Processes
embryonic structures
Neoplastic Stem Cells
Female
Biological Cultures
Stem cell
Research Article
Clinical Oncology
medicine.medical_specialty
Science Policy
Radiation Therapy
Nerve Tissue Proteins
Research and Analysis Methods
OLIG2
03 medical and health sciences
Glioma
medicine
Biomarkers
Tumor
Animals
Humans
Immunoassays
neoplasms
Cell Proliferation
Growth Control
Clinical Genetics
lcsh:R
CD44
Biology and Life Sciences
Cell Biology
Oligodendrocyte Transcription Factor 2
Cell Cultures
medicine.disease
030104 developmental biology
Cell culture
biology.protein
Cancer research
Immunologic Techniques
lcsh:Q
Neoplasm Recurrence
Local
Clinical Medicine
Glioblastoma
Developmental Biology
Zdroj: PLoS ONE
PLoS ONE, Vol 12, Iss 2, p e0172791 (2017)
DOI: 10.26181/22682353.v1
Popis: Glioblastoma (GBM) is a heterogeneous tumor of the brain with a poor prognosis due to recurrence and drug resistance following therapy. Genome-wide profiling has revealed the existence of distinct GBM molecular subtypes that respond differently to aggressive therapies. Despite this, molecular subtype does not predict recurrence or drug resistance and overall survival is similar across subtypes. One of the key features contributing to tumor recurrence and resistance to therapy is proposed to be an underlying subpopulation of resistant glioma stem cells (GSC). CD133 expression has been used as a marker of GSCs, however recent evidence suggests the relationship between CD133 expression, GSCs and molecular subtype is more complex than initially proposed. The expression of CD133, Olig2 and CD44 was investigated using patient derived glioma stem-like cells (PDGCs) in vitro and in vivo. Different PDGCs exhibited a characteristic equilibrium of distinct CD133+ and CD44+ subpopulations and the influence of environmental factors on the intra-tumor equilibrium of CD133+ and CD44+ cells in PDGCs was also investigated, with hypoxia inducing a CD44+ to CD133+ shift and chemo-radiotherapy inducing a CD133+ to CD44+ shift. These data suggest that surveillance and modulation of intra-tumor heterogeneity using molecular markers at initial surgery and surgery for recurrent GBM may be important for more effective management of GBM. ispartof: PLoS One vol:12 issue:2 pages:e0172791- ispartof: location:United States status: published
Databáze: OpenAIRE
Externí odkaz: